A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events.
Phase of Trial: Phase III
Latest Information Update: 19 May 2017
At a glance
- Drugs Bococizumab (Primary)
- Indications Dyslipidaemias; Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Acronyms SPIRE-HR
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 17 Mar 2017 Results of a pooled analysis from SPIRE-HR, SPIRE-LDL, SPIRE-LDL, SPIRE-LL, SPIRE-SI and SPIRE-AI studies (n=4449), published in the New England Journal of Medicine.
- 13 Jul 2016 This trial was completed in Germany (end date: 05-04-2016), according to European Clinical Trials Database.